Although SVR rates varied strongly according to IL28B status, Telaprevir+SoC was much better than SoC alone in all IL28B variants in the ADVANCE (first-line) and REALIZE (second-line—scan down for table) phase-3 studies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.